46 citations
,
February 2012 in “Oncology Reports” This review summarizes existing studies on sorafenib, noting its promising effects in some cancers, but also highlights its limitations and potential synergy when combined with other anticancer treatments.
7 citations
,
October 2019 in “Annals of palliative medicine” This review examines the incidence and management of dermatologic adverse effects from FDA-approved oral targeted cancer therapies, highlighting frequent occurrences like rashes and rarer severe conditions such as Stevens-Johnson Syndrome.
49 citations
,
December 2022 in “Pharmacological Reviews” This review discusses androgen receptor targeting as a potential treatment strategy for triple-negative breast cancer and reports no new experimental outcomes.
1 citations
,
January 2024 in “ACS Medicinal Chemistry Letters” This Patent Highlight discusses recent progress in developing TYK2 inhibitors, which show potential for treating conditions like cancer, alopecia areata, and psoriatic arthritis.
12 citations
,
December 2010 in “Journal of thoracic oncology” This article organizes and lists ongoing and completed clinical trials of novel agents for lung cancer, serving as a reference tool with no new research findings reported.